SEC Company Response from ADMA BIOLOGICS, INC. (ADMA) (CIK 0001368514) (ADMA) — Oct 10, 2019

ADMA BIOLOGICS, INC. (ADMA) (CIK 0001368514)
Date: Oct. 10, 2019 · CIK: 0001368514 · Accession: 0001193805-19-001327

View on Edgar

AI Filing Summary & Sentiment

Sentiment

Urgency

Document Type

Confidence

SEC Posture

Company Posture

Summary

Reasoning

File numbers found in text: 333-234107

Date

October 10, 2019

Author

ADMA Biologics

Form

CORRESP

Company

ADMA BIOLOGICS, INC. (ADMA) (CIK 0001368514)

Letter

VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences Attention: Ada D. Sarmento Re: ADMA Biologics, Inc. Registration Statement on Form S-3 File No. 333-234107

Dear Ms. Sarmento:

In accordance with Rule 461 under the Securities Act of 1933, as amended, we hereby request acceleration of the effective date of the above-referenced registration statement on Form S-3 (the “Registration Statement”) of ADMA Biologics, Inc. (the “Company”). We respectfully request that the Registration Statement become effective as of 4:00 p.m., Eastern Time, on October 15, 2019, or as soon as practicable thereafter. Once the Registration Statement has been declared effective, please confirm that event with our counsel, Morgan, Lewis & Bockius LLP, by calling David C. Schwartz, Esq. at 609.919.6680.

Very truly yours,
ADMA Biologics,
Inc.

Show Raw Text

CORRESP
1
filename1.htm

Brian Lenz

Executive Vice President and Chief Financial Officer

ADMA Biologics, Inc.

465 State Route 17

Ramsey, NJ 07446

October 10, 2019

VIA EDGAR

United States Securities and Exchange Commission

Division of Corporation Finance

Office of Life Sciences

100 F Street, N.E.

Washington, D.C. 20549

Attention: Ada D. Sarmento

 Re: ADMA Biologics, Inc.

                                                                                Registration Statement on Form S-3

                                                                                File No. 333-234107

Dear Ms. Sarmento:

In accordance with Rule 461 under the Securities
Act of 1933, as amended, we hereby request acceleration of the effective date of the above-referenced registration statement on
Form S-3 (the “Registration Statement”) of ADMA Biologics, Inc. (the “Company”). We respectfully request
that the Registration Statement become effective as of 4:00 p.m., Eastern Time, on October 15, 2019, or as soon as practicable
thereafter. Once the Registration Statement has been declared effective, please confirm that event with our counsel, Morgan, Lewis
& Bockius LLP, by calling David C. Schwartz, Esq. at 609.919.6680.

    Very truly yours,

    ADMA Biologics,
Inc.

    By:
    /s/ Brian Lenz

    Brian Lenz

    Executive Vice President and Chief Financial Officer

 CC: David C. Schwartz, Esq., Morgan, Lewis & Bockius LLP

SecProbe.io